Slow cardiac myosin regulatory light chain 2 (MYL2) was down-expressed in chronic heart failure patients

Clinical Cardiology

Volumn 34, Issue 1, 2011, Pages 30-34

  Li, Yuanhong ^a,b   Wu, Gang ^a   Tang, Qizhu ^a   Huang, Congxin ^a   Jiang, Hong ^a   Shi, Lisong ^c   Tu, Xin ^c   Huang, Jinqi ^b   Zhu, Xiaoqing ^b   Wang, Hongli ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Central Hospital of Enshi Autonomous Prefecture   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN LIGHT CHAIN 2; POLYPEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE MUTATION; HEART FAILURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL SOCIETY; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOWN-REGULATION; FEMALE; HEART FAILURE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCARDIUM; MYOSIN LIGHT CHAINS; SEVERITY OF ILLNESS INDEX;

EID: 79251541182     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20832     Document Type: Article

References (22)

1. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [published correction appears in Eur Heart J 2010;12:416]. Eur Heart J 2008; 29: 2388-2442.
2. McMurray JJ, Pfeffer MA., Heart failure. Lancet 2005; 365: 1877-1889.
3. Latronico MV, Elia L, Condorelli G, et al., Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment. Int J Biochem Cell Biol 2008; 40: 1643-1648.
4. Hershberger RE, Cowan J, Morales A, et al., Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009; 2: 253-261.
5. Oka T, Komuro I., Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 2008; 72 (Suppl A): A13-A16.
6. Flavigny J, Richard P, Isnard R, et al., Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med 1998; 76: 208-214.
7. Kabaeva ZT, Perrot A, Wolter B, et al., Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. Eur J Hum Genet 2002; 10: 741-748.
8. Richard P, Charron P, Carrier L, et al., Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107: 2227-2232.
9. Ingles J, Doolan A, Chiu C, et al., Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005; 42: e59.
10. Fokstuen S, Lyle R, Munoz A, et al., A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat 2008; 29: 879-885.
11. Morita H, Rehm HL, Menesses A, et al., Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358: 1899-1908.
12. Møller DV, Andersen PS, Hedley P, et al., The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. Eur J Hum Genet 2009; 17: 1241-1249.
13. Szczesna D, Ghosh D, Li Q, et al., Familial hypertrophic cardiomyopathy mutations in the regulatory light chains of myosin affect their structure, Ca2+ binding, and phosphorylation. J Biol Chem 2001; 276: 7086-7092.
14. Szczesna D, Zhao J, Jones M, et al., Phosphorylation of the regulatory light chains of myosin affects Ca2+ sensitivity of skeletal muscle contraction. J Appl Physiol 2002; 92: 1661-1670.
15. Sherwood JJ, Waller GS, Warshaw DM, et al., A point mutation in the regulatory light chain reduces the step size of skeletal muscle myosin. Proc Natl Acad Sci U S A 2004; 101: 10973-10978.
16. Szczesna-Cordary D, Guzman G, Zhao J, et al., The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice. J Cell Sci 2005; 118: 3675-3683.
17. Wadgaonkar R, Shafiq S, Rajmanickam C, et al., Interaction of a conserved peptide domain in recombinant human ventricular myosin light chain-2 with myosin heavy chain. Cell Mol Biol Res 1993; 39: 13-26.
18. Barth AS, Kuner R, Buness A, et al., Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol 2006; 48: 1610-1617.
19. Asakura M, Kitakaze M., Global gene expression profiling in the failing myocardium. Circ J 2009; 73: 1568-1576.
20. Min KD, Asakura M, Liao Y, et al., Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 2010; 393: 55-60.
21. Maron BJ., Hypertrophic cardiomyopathy: A systemic review. JAMA 2002; 287: 1308-1320.
22. Towbin JA., Hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2009; 32 (Suppl 2): S23-S31.